Document:

Exhibit 4.4

 

FORM OF UNDERWRITERS’ WARRANT AGREEMENT

 

THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE
OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE
OTHER THAN (I) THE BENCHMARK COMPANY, LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA
FIDE OFFICER OR PARTNER OF THE BENCHMARK COMPANY, LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS PURCHASE
WARRANT IS NOT EXERCISABLE PRIOR TO [●], 2019. VOID AFTER 5:00 P.M., EASTERN TIME, [●], 2024.

 

COMMON SHARE
PURCHASE WARRANT

 

For the Purchase
of [●] Common Shares

of

CNS PHARMACEUTICALS,
INC.

 

1. Purchase
Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of THE BENCHMARK COMPANY, LLC (“Holder”),
as registered owner of this Purchase Warrant, to CNS Pharmaceuticals, Inc., a corporation governed by the laws of the state of
Nevada (the “Company”), Holder is entitled, at any time or from time to time from [●], 2019 (the “Commencement
Date”), and at or before 5:00 p.m., Eastern time, [●], 2024, which will be the five-year anniversary of the effective
date of the Company’s Form S-1 registration statement (File No.333-232443) (such date, the “Effective Date”)
(the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up
to [●] common shares of the Company, par value $0.001 (the “Shares”), subject to adjustment as provided
in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close,
then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein.
During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant.
This Purchase Warrant is initially exercisable at $[●] per Share; provided, however, that upon the
occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including
the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified.
The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on
the context.

 

2. Exercise.

 

2.1. Exercise
Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and
delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased
payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or
official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time,
on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented
hereby shall cease and expire.

 

2.2. Cashless
Exercise. In lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company pursuant
to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value of this Purchase Warrant
(or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form
attached hereto, in which event the Company will issue to Holder Shares in accordance with the following formula:

 

	X	=	 	  Y(A-B)    	 	 	 
	 	A   	 	 	 
	Where,	 	 	 	 	 	 	 
	 	 	X	 	=	 	The number of Shares to be issued to Holder;	 
	 	 	Y	 	=	 	The number of Shares for which the Purchase Warrant is being exercised;	 
	 	 	A	 	=	 	The fair market value of one Share; and	 
	 	 	B	 	=	 	The Exercise Price.	 

 

 

 

 

 

    	 	1	 

     

    

 

For
purposes of this Section 2.2, the fair market value of a Share is defined as follows:

 

	 	(i)	if the Company’s common shares are traded on a securities exchange, the value shall be deemed to be the closing price on such exchange prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; or
	 	 	 
	 	(ii)	if the Company’s common shares are actively traded over-the-counter, the value shall be deemed to be the closing bid prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Company’s Board of Directors.

 

2.3. Legend.
Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the “Act”):

 

“The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”),
or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred
except pursuant to an effective registration statement under the Act, or pursuant to an exemption from registration under the Act
and applicable state law which, in the opinion of counsel to the Company, is available.”

 

2.4. Accredited
Investor. The Holder is an “accredited investor” as defined in Rule 501(a) under the Act, and is receiving the
Purchase Warrant pursuant to an exemption from the prospectus requirements of applicable securities laws.

 

2.5. Resale
of Shares. Holder and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance of
the SEC has published Compliance & Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating that
the holder of securities issued in connection with a public offering may not rely upon Rule 144 promulgated under the Act to establish
an exemption from registration requirements under Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively
for the resale of such shares in the following manner: (a) provided that six months has elapsed since the last sale under the registration
statement, an underwriter or finder may resell the securities in accordance with the provisions of Rule 144(c), (e), and (f), except
for the notice requirement; (b) a purchaser of the shares from an underwriter receives restricted securities unless the sale is
made with an appropriate, current prospectus, or unless the sale is made pursuant to the conditions contained in (a) above; (c)
a purchaser of the shares from an underwriter who receives restricted securities may include the underwriter’s holding period,
provided that the underwriter or finder is not an affiliate of the issuer; and (d) if an underwriter transfers the shares to its
employees, the employees may tack the firm’s holding period for purposes of Rule 144(d), but they must aggregate sales of
the distributed shares with those of other employees, as well as those of the underwriter or finder, for a six-month period from
the date of the transfer to the employees. Holder and the Company also acknowledge that the Staff of the Division of Corporation
Finance of the SEC has advised in various no-action letters that the holding period associated with securities issued without registration
to a service provider commences upon the completion of the services, which the Company agrees and acknowledges shall be the closing
of the Offering, and that Rule 144(d)(3)(ii) provides that securities acquired from the issuer solely in exchange for other securities
of the same issuer shall be deemed to have been acquired at the same time as the securities surrendered for conversion (which the
Company agrees is the date of the initial issuance of this Purchase Warrant). In the event that following a request by Holder to
transfer the Shares in accordance with Compliance & Disclosure Interpretation 528.04 counsel for the Company reasonably concludes
that Compliance & Disclosure Interpretation 528.04 no longer may be relied upon as a result of changes in applicable laws,
regulations, or interpretations of the SEC Division of Corporation Finance, or as a result of judicial interpretations not known
by the Company or its counsel on the date hereof (either, a “Registration Trigger Event”), then the Company
shall promptly, and in any event within five (5) business days following the request, provide written notice to Holder of such
determination. As a condition to giving such notice, the Company shall offer Holder a single demand registration right pursuant
to an agreement in form acceptable to the Holder; provided that notwithstanding anything to the contrary, the obligations of the
Company pursuant to this Section 2 shall terminate on the fifth anniversary of the Effective Date. In the absence of such conclusion
by counsel for the Company, the Company shall, upon request of Holder given no earlier than six months after the final closing
of the Offering, instruct its transfer agent to permit the transfer of such shares in accordance with Compliance & Disclosure
Interpretation 528.04, provided that Holder has provided such documentation as shall be reasonably be requested by the Company
to establish compliance with the conditions of Compliance & Disclosure Interpretation 528.04.

 

 

 

 

    	 	2	 

     

    

 

3. Transfer.

 

3.1. General
Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder
will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days
following the Effective Date to anyone other than: (i) THE BENCHMARK COMPANY, LLC (“Benchmark”) or an underwriter
or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of Benchmark or of any such underwriter
or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) cause this Purchase Warrant or the securities
issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(g)(2). After
180 days after the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable securities
laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly
executed and completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith.
Subject to applicable securities laws, the Company shall within five (5) Business Days transfer this Purchase Warrant on the books
of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s)
expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number
as shall be contemplated by any such assignment.

 

3.2. Restrictions
Imposed by the Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company
has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration
under the Act and applicable state securities laws, or (ii) a registration statement or a post-effective amendment to the Registration
Statement relating to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities
and Exchange Commission (the “Commission”) and compliance with applicable state securities law has been established.

 

4. Registration
Rights.

 

4.1. Grant
of Right. The Holder shall have the right for a period of no more than two (2) years from the Effective Date to include the
Shares underlying the Purchase Warrants (collectively, the “Registrable Securities”) as part of any other registration
of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the
Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary
underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion,
impose a limitation on the number of shares of common stock which may be included in the Registration Statement because, in such
underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities
in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

4.2. Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to this Section
4 hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected
by the Holders to represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration,
the Company shall furnish the then Holders of outstanding Registrable Securities with not less than ten (10) days written notice
prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for
each registration statement filed by the Company until such time as all of the Registrable Securities have been registered for
resale under the Act or sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back”
rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention
to file a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number
of times the Holder may request registration under this section; provided, however, that such “piggy-back” registration
rights shall terminate on the fifth (5th) anniversary of the Effective Date in accordance with FINRA Rule 5110(f)(2)(G)(v).

 

 

 

    	 	3	 

     

    

 

4.3. Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of the Securities
Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense or liability (including
all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any
claim whatsoever) to which any of them may become subject under the Act, the Exchange Act or otherwise, arising from such registration
statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify
the Holder(s) pursuant to the underwriting agreement relating to such registration statement (the “Underwriting Agreement”).
The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns,
shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable
attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever)
to which they may become subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on behalf
of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement to the same
extent and with the same effect as the provisions contained in the Underwriting Agreement pursuant to which the underwriters have
agreed to indemnify the Company.

 

4.4. Exercise
of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

4.5. Documents
Delivered to Holders. The Company shall deliver promptly to each Holder participating in the offering requesting the correspondence
and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and
the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff with respect to
the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with
respect to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with
applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and opportunities
to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable
times, during normal business hours, as any such Holder shall reasonably request.

 

4.6. Underwriting
Agreement. If the Company shall enter into an underwriting agreement, pursuant to which Registrable Securities of a Holder
are being registered, such Holders shall not be required to make any representations or warranties to or agreements with the Company
or the underwriters except as they may relate to such Holders, their Shares and their intended methods of distribution.

 

4.7. Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
(i) a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders.

 

5. New
Purchase Warrants to be Issued.

 

5.1. Partial
Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised
or assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase
Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise
Price and/or transfer tax if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered
to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing
the right of the Holder to purchase the number of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised
or assigned.

 

 

 

    	 	4	 

     

    

 

5.2. Lost
Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this
Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver
a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft,
mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

  

6. Adjustments.

 

6.1. Adjustments
to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase Warrant shall
be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1. Share
Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below,
the number of outstanding Shares is increased by a share dividend payable in Shares or by a split up of Shares or other similar
event, then, on the effective day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such
increase in outstanding Shares, and the Exercise Price shall be proportionately decreased.

 

6.1.2. Aggregation
of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the effective
date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding Shares,
and the Exercise Price shall be proportionately increased.

 

6.1.3. Replacement
of Securities Upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding Shares other
than a change covered by Section 6.1.1 or Section 6.1.2 hereof or that solely affects the par
value of such Shares, or in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another
corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation
and that does not result in any reclassification or reorganization of the outstanding Shares), or in the case of any sale or conveyance
to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with
which the Company is dissolved, this Purchase Warrant shall, immediately after such reorganization, reclassification, consolidation,
merger, sale or similar transaction, remain outstanding and shall thereafter, in lieu of or in addition to (as the case may be)
the number of Shares then exercisable under this Purchase Warrant, be exercisable for the kind and number of shares of stock or
other securities or assets of the Company or of the successor person resulting from such transaction to which the Holder would
have been entitled upon such reorganization, reclassification, consolidation, merger, sale or similar transaction if the Holder
had exercised this Warrant in full immediately prior to the time of such reorganization, reclassification, consolidation, merger,
sale or similar transaction and acquired the applicable number of Shares then issuable hereunder as a result of such exercise (without
taking into account any limitations or restrictions on the exercisability of this Purchase Warrant); and, in such case, appropriate
adjustment shall be made with respect to the Holder’s rights under this Purchase Warrant to insure that the provisions of
this Section 6.1.3 hereof shall thereafter be applicable, as nearly as possible, to this Purchase Warrant in relation
to any shares of stock, securities or assets thereafter acquirable upon exercise of this Purchase Warrant (including, in the case
of any consolidation, merger, sale or similar transaction in which the successor or purchasing person is other than the Company,
an immediate adjustment in the Exercise Price to the value per common share reflected by the terms of such consolidation, merger,
sale or similar transaction, and a corresponding immediate adjustment to the number of Shares acquirable upon exercise of this
Purchase Warrant without regard to any limitations or restrictions on exercise, if the value so reflected is less than the Exercise
Price in effect immediately prior to such consolidation, merger, sale or similar transaction). The provisions of this Section
6.1.3 shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers, sales or similar transactions.
The Company shall not effect any such reorganization, reclassification, consolidation, merger, sale or similar transaction unless,
prior to the consummation thereof, the successor person (if other than the Company) resulting from such reorganization, reclassification,
consolidation, merger, sale or similar transaction, shall assume, by written instrument substantially similar in form and substance
to this Purchase Warrant and satisfactory to the Holder, the obligation to deliver to the Holder such shares of stock, securities
or assets which, in accordance with the foregoing provisions, such Holder shall be entitled to receive upon exercise of this Warrant.

 

 

 

    	 	5	 

     

    

 

6.1.4. Changes
in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section
6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are
stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new
Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring
after the Commencement Date or the computation thereof.

 

6.2. Substitute
Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company
with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in
any reclassification or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction
or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase
Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant)
to receive, upon exercise of such Purchase Warrant, the kind and amount of shares and other securities and property receivable
upon such consolidation or share reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such
Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale
or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided
for in this Section 6. The above provision of this Section shall similarly apply to successive consolidations or share
reconstructions or amalgamations.

 

6.3. Elimination
of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares upon the
exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being
the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may
be, to the nearest whole number of Shares or other securities, properties or rights.

 

7. Reservation
and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose
of issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be
issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of
the Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall
be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. As long as the
Purchase Warrants shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable
upon exercise of the Purchase Warrants to be listed (subject to official notice of issuance) on all national securities exchanges
(or, if applicable, quoted on the OTC Bulletin Board or any successor trading market) on which the Company’s common shares
may then be listed and/or quoted.

 

8. Certain
Notice Requirements.

 

8.1. Holder’s
Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice
of such event at least ten (10) days prior to the date fixed as a record date or the date of closing the transfer books for the
determination of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription
rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record
date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver
to each Holder a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that
such notice is given to the shareholders.

 

 

 

 

    	 	6	 

     

    

 

8.2. Events
Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or
more of the following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling
them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise
than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company,
(ii) the Company shall offer to all the holders of its Shares any additional shares of capital stock of the Company or securities
convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor,
or (iii) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction
or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed.

 

8.3. Notice
of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall
describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the
Company’s Chief Financial Officer.

 

8.4. Transmittal
of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall
be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company,
to following address or to such other address as the Company may designate by notice to the Holders:

 

If
to the Holder:

 

The
Benchmark Company, LLC

150
East 58th Street, 17th Floor

New
York, New York 10155

Attention:
Richard Messina, President

 

 

If
to the Company:

 

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

Attention: [●]

Fax No: [●] 

 

9. Miscellaneous.

 

9.1. Amendments.
The Company and Benchmark may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders
in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with
any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company
and Benchmark may deem necessary or desirable and that the Company and Benchmark deem shall not adversely affect the interest of
the Holders. All other modifications or amendments shall require the written consent of and be signed by the party against whom
enforcement of the modification or amendment is sought.

 

9.2. Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3. Entire
Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

 

 

 

    	 	7	 

     

    

 

9.4. Binding
Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and
their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.

 

9.5. Governing
Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. Each of the Company and the
Holder hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant
shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the
Company and the Holder hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company or the Holder may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company and the Holder in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred
in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
of its shareholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.

 

9.6. Waiver,
etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not
be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or
any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase
Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be
effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any
other or subsequent breach, non-compliance or non-fulfillment.

 

9.7. Exchange
Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any
time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Benchmark enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash
or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Signature Page
Follows]

 

 

 

 

 

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the [●] day of [●],
2019.

 

CNS PHARMACEUTICALS, INC.

 

	By:	 	 
	 	Name:	 
	 	Title:	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	9	 

     

    

 

[Form to be
used to exercise Purchase Warrant]

 

Date:                                

 

The
undersigned hereby elects irrevocably to exercise the Purchase Warrant for [●] common shares, no par value (the “Shares”),
of CNS Pharmaceuticals, Inc., a corporation governed by the laws of the state of Nevada (the “Company”), and
hereby makes payment of $ (at the rate of $[●] per Share) in payment of the Exercise Price pursuant thereto. Please issue
the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.

 

or

 

The
undersigned hereby elects irrevocably to convert its right to purchase [●] Shares of the Company under the Purchase Warrant
for [●] Shares, as determined in accordance with the following formula:

 

	 	 	 	 	 	 	 	 
	X    	 	=	 	    Y(A-B)    	 	 	 
	 	 	A	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	Where,	 	 	 	 	 	 	 	 	 	 
	 	 	 	 
	 	 	X	 	=	 	The number of Shares to be issued to Holder;	 
	 	 	Y	 	=	 	The number of Shares for which the Purchase Warrant is being exercised;	 
	 	 	A	 	=	 	The fair market value of one Share which is equal to $[●]; and	 
	 	 	B	 	=	 	The Exercise Price which is equal to $[●] per share	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

The
undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement
with respect to the calculation shall be resolved by the Company in its sole discretion.

 

Please
issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable,
a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

 

Signature

 

Signature Guaranteed

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

	 	 	 
	Name:	 	 
	 	(Print in Block Letters)	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or
enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by
a firm having membership on a registered national securities exchange.

 

 

 

    	 	10	 

     

    

 

[Form to be used to assign Purchase Warrant]

 

ASSIGNMENT

 

(To be executed by the registered Holder
to effect a transfer of the within Purchase Warrant):

 

FOR
VALUE RECEIVED, [●] does hereby sell, assign and transfer unto the right to purchase common shares, no par value, of CNS
Pharmaceuticals, Inc., a corporation governed by the laws of the state of Nevada (the “Company”), evidenced
by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated                                            

 

Signature

 

Signature Guaranteed

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or
by a firm having membership on a registered national securities exchange.

 

 

 

 

 

 

 

 

    	 	11Exhibit 10.8

 

June 28, 2019

 

Dr. Donald Picker

Via Email

 

Re:       Offer of Employment

 

Dear Dr. Picker:

 

It is my pleasure to offer you a position
with CNS Pharmaceuticals, Inc., (the “Company”). This letter is intended to set forth the terms of the offer.

 

If you accept this offer you would become
Chief Science Officer for the Company, commencing June 28, 2019. You will report primarily to the Company’s CEO.

 

Your annual salary will commence upon the
closing of our initial public offering and will be $91,000, payable semi-monthly on the same basis as all other employees and subject
to any applicable withholding or other taxes and is based on the presumption that you will dedicate 25% of your work time to the
Company, defined as no less than 10 hours per week. In addition, you will be eligible for an annual bonus of up to 36% of your
base salary, which will be prorated based on the number of days during the compensation year (which runs from January 1 to December
31) worked, and the final determination on the amount of the bonus will be made by the Company’s compensation committee,
in its sole discretion, based on criteria established by the Company. Upon execution of this offer letter, commencement of your
employment, and approval of the Compensation Committee of the Board of Directors, you will receive a grant (the “Stock
Option Grant”) of stock options (the “Stock Options”) to purchase 100,000 shares of the Company’s
common stock at an exercise price per share of $2.00. The Stock Options shall have a term of ten years and shall vest in four (4)
equal installments (or 25,000 shares each installment) on each of the succeeding four anniversary dates of your start date (i.e.
the first such installment shall vest on the first anniversary of the start date), provided that you are serving in the position
as described above on each vesting date. The Stock Option Grant shall be made pursuant to the CNS Pharmaceuticals, Inc. 2018 Stock
Plan, as amended from time to time, and shall in all respects be subject to the terms and conditions of such plan.

 

While you are employed by the Company on
a part-time basis, you will be entitled to such employee benefits as are generally enjoyed by the Company’s other part-time
employees. Paid time off must be approved by the CEO. All benefits are subject to change by the Company and according to its policies.

 

Notwithstanding anything else herein, it
is understood that your employment with the Company will be “at will” and may be terminated by you or the Company at
any time and for any reason.

 

In order to protect the Company, you have
assured us that:

 

(i)       you
have described your background truly and completely, revealing all information that may have impacted the Company’s decision
to offer you employment;

 

(ii)      your
employment with the Company will not violate any obligation you may have; and

 

(iii)     you
have no confidential material, documents, or other property of any former employer or other person or entity that will be brought
or utilized in any work performed for the Company under this Agreement.

 

 

 

 

 

 

    	 	1	 

     

    

 

Contemporaneously with your execution of
this letter, you acknowledge that you are receiving Confidential Information of the Company or others dealing with the Company
and that the Company will be expending resources to provide you with unique training with regard to the drugs and technology the
Company is developing. You acknowledge that the Confidential Information provided to you and the unique training you will get is
valuable consideration for your promises in this letter. The term “Confidential Information” means any information
concerning the Company’s business, technology, business relationships, financial affairs, trade secrets or any other proprietary
information, which may be oral, written, graphic, machine-readable or in other tangible form, that the Company has not disclosed
to the general public. “Confidential Information” also means all information whether of the Company or received by
the Company from its licensors, licensees, suppliers, customers or third parties that the Company treats as confidential during
the term of your employment whether or not the information is regarded as a “trade secret” as defined by law. You acknowledge
that the Confidential Information constitutes valuable trade secrets and agree to use the Confidential Information solely in accordance
with the provisions of this letter agreement.

 

You agree not to disclose any Confidential
Information to any person, without the Company’s prior written consent, other than agents of the Company who need to know
the Confidential Information in order to fulfill their responsibilities for the Company. You agree not to use the Confidential
Information for any purpose other than to fulfill your responsibilities for the Company. You further agree to safeguard the confidentiality
of the Confidential Information by cooperating with the Company; taking all precautions the Company requires; using your best efforts
to prevent the unauthorized disclosure of any Confidential Information; and delivering to the Company all copies of Confidential
Information in your possession, custody, or control upon the earlier request of the Company or the termination of your employment.
These limitations do not apply to information that (i) is publicly available, (ii) was obtained by you from third parties without
restrictions on disclosure, (iii) you knew prior to entering this letter agreement, (iv) was independently developed by you without
the use of Confidential Information, or (v) is required to be disclosed by order of a court or other governmental entity.

 

During your employment you agree to make
full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements,
processes, algorithms, databases, formulae, techniques, trade secrets and other works of authorship (“Created Materials”)
whether or not patentable or copyrightable, that are created, made, conceived, or reduced to practice (alone or jointly with others
or under your direction) during the period of your employment with the Company so long as it is applicable to the Company’s
business.

 

With respect to Created Materials, you
agree that:

 

(i)         all
work performed by you, including any copyrightable work, is on a “work for hire” basis and will be the sole and exclusive
property of the Company, and you hereby assign and transfer to the Company and its successors all of your rights and interests
in Created Materials to the Company;

 

(ii)        you
will complete and keep documentation of the conception, development and reduction to practice of Created Materials;

 

(iii)       you
will disclose all Created Materials, including your documentation, to the Company promptly and completely;

 

(iv)       you
will cooperate fully with the Company, both during and after the term of your employment, to the procurement, maintenance and enforcement
of the Company’s intellectual property rights in the Created Materials;

 

 

 

 

    	 	2	 

     

    

 

(v)       you
will sign any documents and assist the Company in any applications or proceedings that may be necessary to secure for the Company
the ownership or protection of the Created Materials and any patents, copyrights or other proprietary rights related to the Created
Materials. If necessary for the Company, you agree to do these things even after your employment with the Company is over, in which
case the Company will pay you a reasonable fee for the time that you spend on its behalf and reimburse you for any ordinary and
necessary out of pocket expenses that you incur; and

 

(vi)       you
will deliver to the Company all Created Materials as well as all materials you received from Company for use in creating Created
Materials when your employment with Company is over.

 

Your obligations to the Company with respect
to Confidential Information and Created Materials, however, will continue after your employment with the Company is terminated.
You also agree that the Company may assign this letter agreement to any successor company or entity.

 

You agree to be bound by the terms of this
letter agreement for the duration of your employment with the Company, throughout minor changes in responsibility and compensation.
You understand that you may be called upon to support the Company by occasionally completing tasks outside your general job description.
You agree that such temporary assignments are not material alterations of your employment relationship with the Company. You agree
that unless and until your employment relationship changes permanently and materially such that a new employment contract is entered
into you will remain bound by the terms of this letter agreement.

 

Any controversy or claim arising out of
or relating to this letter agreement, its formation, or the breach thereof, shall be settled by a court of competent jurisdiction
in Harris County, Texas and you agree to submit to personal jurisdiction and venue there.

 

This letter is governed by and interpreted
according to the laws of the State of Texas and you and the Company both agree to waive any right to a jury trial.

 

If this letter accurately states our agreement
about your employment, please sign the enclosed copy of the letter and return it to me whereupon this letter agreement will then
be effective as of your first day of employment and will be the complete agreement between you and the Company with respect to
your employment and will supersede our previous discussions and communications.

 

 

Very truly yours,

 

CNS Pharmaceuticals, Inc.

 

 

By:______________________

John Climaco

Chief Executive Officer

 

 

Agreed and Accepted:

 

 

	 	 	 	 
	Donald Picker	 	Dated	 

 

 

 

 

 

 

 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]